September 7 is World Duchenne Awareness Day. In celebration of this awareness-raising event, SOM Biotech goes casual at the office and joins the "Jeans Day" campaign of Parent Project Muscular Dystrophy. SOM Biotech team Duchenne muscular dystrophy is the most common muscular dystrophy in children. It is a progressive disorder that causes muscles to become…

BIT's 16th Annual Congress of International Drug Discovery Science and Technology (IDDST 2018) was held on 16th-18th August 2018 in Boston, Massachusetts with the theme "Rethinking the Next Big Things in Pharma Innovations". The congress hosted leading scientists and professionals from the academia and industry worldwide, to discuss the latest developments in drug discovery and therapy. SOM Biotech CEO…

The SOMCT02 trial has recruited its first patient on 8th August 2018 at the Hospital Clínic de Barcelona, under the leadership of Dr. Esteban Muñoz. This indicates that the trial is now fully underway. SOMCT02 is a Phase 2a proof-of-concept and is designed as a randomized, double-blind, placebo-controlled, 2-arm, 27-week study to evaluate the safety and efficacy of…

BARCELONA, Spain and CAMBRIDGE, Massachusetts, July 17, 2018 -- SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs for orphan indications in the Central Nervous System, has announced today the successful initiation of Phase 2a clinical trial of its repurposed compound SOM3355 for the treatment of the chorea movements associated to Huntington's disease. The Principal Investigator of the study is…

This year, SOM Biotech was invited to present to the Investors Circle of the Business Angel Network of BIO.NRW on the 9th of July in Dusseldorf, Germany. SOM Biotech CEO Dr. Raúl Insa presented the company, highlighting its proven business model to the attending investors. The presentation platform is held three to four times a year in a strictly confidential…

SOM Biotech has received on 18th June 2018 the approval of the Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct its Phase IIa, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of SOM3355 in patients with choreic movements associated with Huntington's disease. The study will be conducted in four major hospitals in…